Needham & Company Downgrades OncoGenex Pharmaceuticals (OGXI) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St futures muted as bond yields resume climb; Walmart drops after results
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Crypto stocks surge as Bitcoin short squeeze hits record $2.7B
- Deere shares climb as fiscal Q3 earnings and revenue top estimates
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
RBC Capital Downgrades OncoGenex Pharmaceuticals (OGXI) to Sector Perform
April 29, 2014 7:56 AM EDTRBC Capital downgraded OncoGenex Pharmaceuticals (NASDAQ: OGXI) from Outperform to Sector Perform with a price target of $4.50 (from $19.00).
For an analyst ratings summary and ratings history on OncoGenex Pharmaceuticals click here. For more ratings news on OncoGenex Pharmaceuticals click here.
Shares of OncoGenex Pharmaceuticals closed at $3.85 yesterday.
... More